314.00
+2.21%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About BioArctic
Its shares trade on Nasdaq Stockholm under the ticker BIOA B.ST. It has been listed since 12 October 2017. In the fiscal year to 31 December 2025, it reported net income of SEK 1.02bn. At that date it held total assets of SEK 2.58bn and shareholders' equity of SEK 1.97bn.
BioArctic AB engages in the research and development of modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson's disease. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2017-10-12. The firm focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The firm owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The firm's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The firm also operates through SpineMedical AB.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Oct 2017
- Employees
- 43
- Website
- bioarctic.se ↗
Leadership
Pay as last reported
- Dr. Eugen SteinerIndependent Chairman of the BoardSEK 830,000
- Ms. Gunilla OsswaldPresident, Chief Executive OfficerSEK 9.8m
- Mr. Anders Martin-LoefChief Financial Officer, Company Secretary
- Ms. Rebecca KastellVice President, Head of Human Resource
- Mr. Mikael MogeVice President - Chemistry, Manufacturing and ControlSEK 229,000
- Ms. Biljana RizoskaVice President - Research, Head of Research
- Ms. Emilie SmithGeneral Counsel, Head of Legal & IP
- Mr. Oskar BossonHead of Investor Relations and Communications
- Dr. Johanna FaltingChief R&D Officer, Head of Research & Development
- Ms. Anna-kaija GroenbladChief Commercial Officer
- Ms. Gabrielle HillertChief Medical Officer, Head of Clinical & Regulatory Affairs
- Mr. Par GellerforsDirectorSEK 387,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 75
- Environment
- 85
- Social
- 95
- Governance
- 43
- Direct emissions (scope 1)
- 1 t
- Energy emissions (scope 2)
- 1.87 t
- Value chain emissions (scope 3)
- 10,721.7 t
- Women in the workforce
- 64.48598%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- BioArctic AB benefits from several strengths that contribute to its success in the market. These include:
Weaknesses
- Despite its strengths, BioArctic AB also faces certain weaknesses that could pose challenges to its growth and competitiveness:
Opportunities
- BioArctic AB can leverage various opportunities to further expand its market presence and achieve sustainable growth:
Threats
- BioArctic AB should be wary of potential threats that could impact its business operations and future prospects:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.